169 related articles for article (PubMed ID: 37746082)
1. Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients.
De Falco V; Vitale P; Brancati C; Cicero G; Auriemma A; Addeo R
Front Med (Lausanne); 2023; 10():1252407. PubMed ID: 37746082
[TBL] [Abstract][Full Text] [Related]
2. Survival Benefit of Metformin as an Adjuvant Treatment for Head and Neck Cancer: A Systematic Review and Meta-Analysis.
Jiao Y; Liu D; Sun Y; Chen Z; Liu S
Front Pharmacol; 2022; 13():850750. PubMed ID: 35645803
[No Abstract] [Full Text] [Related]
3. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
4. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
6. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.
Al Hilli MM; Bakkum-Gamez JN; Mariani A; Cliby WA; Mc Gree ME; Weaver AL; Dowdy SC; Podratz KC
Gynecol Oncol; 2016 Feb; 140(2):270-6. PubMed ID: 26607780
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.
Arrieta O; Varela-Santoyo E; Soto-Perez-de-Celis E; Sánchez-Reyes R; De la Torre-Vallejo M; Muñiz-Hernández S; Cardona AF
BMC Cancer; 2016 Aug; 16():633. PubMed ID: 27519177
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.
Marín-Jiménez JA; Oliva M; Peinado Martín P; Cabezas-Camarero S; Plana Serrahima M; Vázquez Masedo G; Lozano Borbalas A; Cabrera Martín MN; Esteve A; Iglesias Moreno MC; Vilajosana Altamis E; Arribas Hortigüela L; Taberna Sanz M; Pérez-Segura P; Mesía R
Front Oncol; 2022; 12():953020. PubMed ID: 35936723
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
10. Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
Stokes WA; Eguchi M; Amini A; Hararah MK; Ding D; McDermott JD; Bradley CJ; Karam SD
Oral Oncol; 2018 Sep; 84():12-19. PubMed ID: 30115470
[TBL] [Abstract][Full Text] [Related]
11. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
13. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study.
Wang HC; Liu PL; Lo PC; Chang YT; Chan LP; Yeh TJ; Hsiao HH; Cho SF
PeerJ; 2020; 8():e9862. PubMed ID: 32974098
[TBL] [Abstract][Full Text] [Related]
14. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
18. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
19. Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Lerner MZ; Mor N; Paek H; Blitzer A; Strome M
Ann Otol Rhinol Laryngol; 2017 Apr; 126(4):340-343. PubMed ID: 28103701
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of metformin in the treatment of estrogen-dependent endometrial carcinoma complicated with type 2 diabetes mellitus and analysis of its prognosis.
Deng Y; Wang J; Li W; Xiong W; Wang X
J BUON; 2020; 25(3):1534-1540. PubMed ID: 32862601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
